{"organizations": [], "uuid": "5d69ed4e63c1b65916da9a25d8431dd55e2d823d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-theravance-biopharma-and-mylan-ann/brief-theravance-biopharma-and-mylan-announce-fda-acceptance-of-new-drug-application-for-revefenacin-idUSASB0C2QY", "country": "US", "domain_rank": 408, "title": "BRIEF-Theravance Biopharma And Mylan Announce FDA Acceptance Of New Drug Application For Revefenacin", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-29T15:38:00.000+02:00", "replies_count": 0, "uuid": "5d69ed4e63c1b65916da9a25d8431dd55e2d823d"}, "author": "", "url": "https://www.reuters.com/article/brief-theravance-biopharma-and-mylan-ann/brief-theravance-biopharma-and-mylan-announce-fda-acceptance-of-new-drug-application-for-revefenacin-idUSASB0C2QY", "ord_in_thread": 0, "title": "BRIEF-Theravance Biopharma And Mylan Announce FDA Acceptance Of New Drug Application For Revefenacin", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "mylan announce fda", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "mylan", "sentiment": "none"}, {"name": "pdufa", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "drug application for revefenacin reuters staff", "sentiment": "none"}, {"name": "theravance biopharma inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 41 PM / Updated 10 minutes ago BRIEF-Theravance Biopharma And Mylan Announce FDA Acceptance Of New Drug Application For Revefenacin Reuters Staff 1 Min Read \nJan 29 (Reuters) - Theravance Biopharma Inc: \n* THERAVANCE BIOPHARMA AND MYLAN ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR REVEFENACIN (TD-4208) IN ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE \n* THERAVANCE BIOPHARMA INC - FDA HAS ASSIGNED A PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE OF NOVEMBER 13, 2018 \n* THERAVANCE BIOPHARMA - ‍ FDA INDICATED IT DOES NOT CURRENTLY PLAN TO CONVENE AN ADVISORY COMMITTEE MEETING TO DISCUSS NDA FOR REVEFENACIN (TD-4208)​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-29T15:38:00.000+02:00", "crawled": "2018-01-29T16:04:21.012+02:00", "highlightTitle": ""}